Crispr Therapeutics Ag logo

CRSP

Crispr Therapeutics Ag

$63.56

Earnings Summary

Revenue
$0.5Mn
Net Profits
$-116.59Mn
Net Profit Margins
-23133.13%

Highlights

Revenue:

Crispr Therapeutics Ag’s revenue fell -99.5% since last year same period to $0.5Mn in the Q1 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated -99.75% fall in its revenue since last 3-months.

Net Profits:

Crispr Therapeutics Ag’s net profit fell -119.71% since last year same period to $-116.59Mn in the Q1 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated -230.49% fall in its net profits since last 3-months.

Net Profit Margins:

Crispr Therapeutics Ag’s net profit margin fell -43493.96% since last year same period to -23133.13% in the Q1 2024. On a quarterly growth basis, Crispr Therapeutics Ag has generated -51882.68% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Crispr Therapeutics Ag post its latest quarter earnings

EPS Estimate Current Quarter
-1.33
EPS Estimate Current Year
-1.33

Highlights

EPS Estimate Current Quarter:

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.33 - a -1800% fall from last quarter’s estimates.

EPS Estimate Current Year:

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.33.

Key Ratios

Key ratios of the Crispr Therapeutics Ag post its Q1 2024 earnings

Earning Per Share (EPS)
-1.43
Return on Assets (ROA)
-0.08
Return on Equity (ROE)
-0.11

Highlights

Earning Per Share (EPS):

Crispr Therapeutics Ag’s earning per share (EPS) fell -113.43% since last year same period to -1.43 in the Q1 2024. This indicates that the Crispr Therapeutics Ag has generated -113.43% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Crispr Therapeutics Ag’s return on assets (ROA) stands at -0.08.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Crispr Therapeutics Ag’s return on equity (ROE) stands at -0.11.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-08
-1.33
-1.43
-7.52%